Delivery Order SPE2DB22D2206-SPE2DB25FJG55
- Not listed
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $5,429.76 for Cathflo Activase 2 mg vials on August 14, 2025, with an ultimate completion date of August 15, 2025. This firm fixed-price contract represents a non-competitive delivery order issued under AmerisourceBergen's existing Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. The product will be delivered to...
- The Defense Logistics Agency awarded a $2,626.75 firm fixed price delivery order to AmerisourceBergen Drug Corp for Cathflo Activase 2 mg vials, with an ultimate completion date of August 15, 2025. This non-set-aside competitive award was issued on August 14, 2025, and represents a child order under AmerisourceBergen's larger indefinite delivery contract with DLA. The product will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $1,357.44 to AmerisourceBergen Drug Corp for the supply of Cathflo Activase 2 mg vials. This firm fixed-price delivery order was issued on August 20, 2025, with an ultimate completion date of August 21, 2025, and represents a non-set-aside competitive award. The product will be performed at the awardee's location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, one of the nation's largest pharmaceutical distributors and...
- The Defense Logistics Agency awarded a delivery order valued at $12,949.43 to AmerisourceBergen Drug Corp for the supply of Cathflo Activase 2 mg vials under a firm fixed-price contract. This non-set-aside award, issued on July 28, 2025, with an ultimate completion date of July 29, 2025, represents a routine pharmaceutical procurement from the prime contractor's corporate office located in Conshohocken, Pennsylvania. The delivery order is executed under AmerisourceBergen Drug Corp's larger...
- The Defense Logistics Agency awarded a delivery order valued at $1,838.12 to AmerisourceBergen Drug Corp for Cathflo Activase 2 mg vials, with an ultimate completion date of June 3, 2025. This non-set-aside, firm fixed price delivery order represents a competitive award to the pharmaceutical distributor for medical supply provision supporting federal healthcare needs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical and healthcare solutions...
- The Defense Logistics Agency awarded a $2,262.40 firm fixed price delivery order to AmerisourceBergen Drug Corp for Cathflo Activase 2 mg vials, with an ultimate completion date of August 19, 2025. This non-set-aside competitive award represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The product will be performed at AmerisourceBergen's...
- The Defense Logistics Agency awarded a $7,481.79 delivery order to AmerisourceBergen Drug Corp for Cathflo Activase 2 mg vials, a thrombolytic medication used to restore function to central venous access devices. This competitively awarded, firm fixed price contract was issued on April 9, 2025, with an ultimate completion date of April 10, 2025, and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The contract carries no set-aside designation, reflecting...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on July 3, 2025, for the supply of Cathflo Activase 2 mg vials with a ceiling value of $33,396.04. This firm fixed-price delivery order, with an ultimate completion date of July 7, 2025, represents a competitive award with no set-aside designation. The contract will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, where the company maintains...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $2,374.60 for Cathflo Activase 2 mg vials, effective July 24, 2025, with an ultimate completion date of July 25, 2025. This firm fixed price delivery order was awarded without a set-aside designation through open competition and will be performed at the contractor's Conshohocken, Pennsylvania facility. Cathflo Activase is a thrombolytic agent used in medical settings to restore function to occluded...
- The Defense Logistics Agency awarded a delivery order valued at $16,297.10 to AmerisourceBergen Drug Corp for the supply of Cathflo Activase 2 mg vials, a thrombolytic medication used in medical applications. The contract was executed as a firm fixed-price delivery order on July 31, 2025, with an ultimate completion date of August 1, 2025, and does not include a set-aside designation. Performance will be fulfilled at the vendor's facility in Conshohocken, Pennsylvania. This delivery order...
- SPE2DB22D2206Indefinite Delivery Contract
- SPE2DB22D2206-SPE2DB25FJG55Delivery Order
The Defense Logistics Agency awarded a $7,372.02 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Cathflo Activase 2 mg vials, with an ultimate completion date of August 7, 2025. This non-set-aside delivery order was competitively awarded on August 6, 2025, with performance at the contractor's Conshohocken, Pennsylvania location. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Pennsylvania, serves as a critical vendor for federal medical procurement, particularly supporting military and veteran healthcare systems through the Defense Logistics Agency's Medical Supply Chain. This delivery order is issued under AmerisourceBergen Drug Corp's existing Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, a $999,999,999 global pharmaceutical support vehicle running through December 2026. The IDC enables the contractor to supply a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs worldwide, including specialty medications, brand-name and generic drugs, vaccines, and related medical commodities. The Cathflo Activase delivery represents one of numerous competitively awarded orders executed under this prime vendor contract vehicle, demonstrating the contractor's continued capability to fulfill federal medical supply requirements across multiple therapeutic domains.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.4k | 8/6/25 |